Catalyst Pharmaceuticals (NASDAQ:CPRX) Given “Buy” Rating at Bank of America

Bank of America reissued their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Thursday,Benzinga reports. They currently have a $30.00 price target on the biopharmaceutical company’s stock.

CPRX has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Truist Financial raised their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Stephens began coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 3rd. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $32.14.

Catalyst Pharmaceuticals Stock Up 16.7 %

Shares of NASDAQ:CPRX opened at $22.80 on Thursday. Catalyst Pharmaceuticals has a fifty-two week low of $13.12 and a fifty-two week high of $24.27. The firm’s 50-day simple moving average is $21.75 and its 200-day simple moving average is $19.88. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 19.32, a PEG ratio of 3.35 and a beta of 0.79.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last quarter. Corporate insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Oliver Luxxe Assets LLC raised its holdings in Catalyst Pharmaceuticals by 103.5% in the 4th quarter. Oliver Luxxe Assets LLC now owns 69,250 shares of the biopharmaceutical company’s stock valued at $1,445,000 after acquiring an additional 35,225 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 25.5% during the fourth quarter. CWA Asset Management Group LLC now owns 33,698 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 6,853 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares during the period. Franklin Resources Inc. increased its stake in Catalyst Pharmaceuticals by 3.4% in the third quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock valued at $1,221,000 after purchasing an additional 1,967 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in Catalyst Pharmaceuticals during the third quarter worth about $667,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.